Jon Unosson
Associerad forskare vid Institutionen för kirurgiska vetenskaper; Kärlkirurgi; RedCap MAAAGI Wanhainen
- Besöksadress:
- Akademiska sjukhuset, ingång 70, 1 tr
751 85 UPPSALA - Postadress:
- Akademiska sjukhuset, ingång 70, 1 tr
751 85 UPPSALA
Specialistläkare vid Institutionen för kirurgiska vetenskaper; Gastrointestinalkirurgi
- E-post:
- jon.unosson@uu.se
- Besöksadress:
- Akademiska sjukhuset, ingång 70, 1 tr
751 85 UPPSALA - Postadress:
- Akademiska sjukhuset, ingång 70, 1 tr
751 85 UPPSALA
- Akademiska meriter:
- MD,PhD
Mer information visas för dig som medarbetare om du loggar in.
Publikationer
Senaste publikationer
- European Multicentric Experience With Fenestrated-branched ENDOvascular Stent Grafting After Previous FAILed Infrarenal Aortic Repair The EU-FBENDO-FAIL Registry (2023)
- Comparison of Early and Mid-Term Outcomes After Fenestrated-Branched Endovascular Aortic Repair in Patients With or Without Prior Infrarenal Repair (2022)
- Inhibition of angiotensin-induced aortic aneurysm by metformin in apolipoprotein E-deficient mice (2021)
- Association Between Metformin Prescription and Abdominal Aortic Aneurysm Growth and Clinical Events (2021)
- Acute cardiovascular effects of controlled exposure to dilute Petrodiesel and biodiesel exhaust in healthy volunteers (2021)
Alla publikationer
Artiklar
- European Multicentric Experience With Fenestrated-branched ENDOvascular Stent Grafting After Previous FAILed Infrarenal Aortic Repair The EU-FBENDO-FAIL Registry (2023)
- Comparison of Early and Mid-Term Outcomes After Fenestrated-Branched Endovascular Aortic Repair in Patients With or Without Prior Infrarenal Repair (2022)
- Inhibition of angiotensin-induced aortic aneurysm by metformin in apolipoprotein E-deficient mice (2021)
- Association Between Metformin Prescription and Abdominal Aortic Aneurysm Growth and Clinical Events (2021)
- Acute cardiovascular effects of controlled exposure to dilute Petrodiesel and biodiesel exhaust in healthy volunteers (2021)
- Metformin Prescription Associated with Reduced Abdominal Aortic Aneurysm Growth Rate and Reduced Chemokine Expression in a Swedish Cohort (2021)
- The Metformin for Abdominal Aortic Aneurysm Growth Inhibition (MAAAGI) Trial (2021)